PLATINUM-RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug azenosertib takes on Chemo-Resistant ovarian cancer in phase 3 trial
Disease control Recruiting nowThis phase 3 study tests whether a new drug called azenosertib works better than standard chemotherapy for people with a specific type of ovarian cancer that no longer responds to platinum-based treatments. The trial enrolls 420 women whose tumors have a high level of a protein c…
Matched conditions: PLATINUM-RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for ovarian cancer: targeted drug R-DXd enters key trial
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. The drug is designed to target and kill cancer cells while sparing healthy ones. About 860 participants…
Matched conditions: PLATINUM-RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
Phase: PHASE2, PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New immunotherapy cocktails aim to outsmart resistant ovarian cancer
Disease control Recruiting nowThis Phase 2 study tests several immunotherapy drug combinations in women with platinum-resistant high-grade serous ovarian cancer, a type that no longer responds to standard chemotherapy. About 60 participants will receive one of five immunotherapy regimens to see which best shr…
Matched conditions: PLATINUM-RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for Platinum-Resistant ovarian cancer: PLX038 trial launches
Disease control Recruiting nowThis Phase II trial tests a drug called PLX038 in 43 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if it shrinks tumors a…
Matched conditions: PLATINUM-RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC